Preclinical evaluation of glycan-targeting monoclonal antibodies for bimodal near-infrared fluorescence and photoacoustic imaging of gastrointestinal cancers.
6 June 2025. doid: 10.1186/s13550-025-01258-y
Houvast RD, Sier VQ, van Duijvenvoorde M, Baart VM, Schomann T, Chua J, Vankemmelbeke M, Durrant LG, Krijgsman D, de Heer P, Hassing GJ, Mieog JSD, Crobach ASLP, Burggraaf J, Kuppen PJK, Vahrmeijer AL
View publicationNear-infrared fluorescence (NIRF) imaging assists surgeons intraoperatively to achieve radical resection of malignant tissue with one centimeter depth and can be supplemented with photoacoustic imaging to increase depth-of-view. Tumor-associated carbohydrate antigens are promising targets for tumor imaging with potential advantages over protein targeting. This study preclinically evaluates the anti-glycan tracers CH88.2-800CW (anti-Le) and CH129-800CW (anti-sdi-Le) for bimodal NIRF/PA imaging of gastrointestinal cancers.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
